Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax COIN Option Income Strategy ETF (CONY) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

YieldMax COIN Option Income Strategy ETFTrade
Ginkgo Bioworks Holdings IncTrade

Price performance (Past 24H)

Key statistics

YieldMax COIN Option Income Strategy ETF vs Ginkgo Bioworks Holdings Inc — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $18.03, while Ginkgo Bioworks Holdings Inc trades at $7.41 (market cap $505.73M). The key difference: Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

CONYDNA
Sector
Income / Options OverlayHealth
52-Week High
$76.50$16.14
52-Week Low
$17.80$5.48
Market Cap
$505.73M
Enterprise Value
$607.68M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax COIN Option Income Strategy ETF

CONY trades at $18.05, down 0.11% with a bearish technical signal from moving averages. The ETF shows weekly dividend distributions but lacks fundamental valuation metrics. Recent news highlights investor losses despite high yield promises, with articles questioning the fund's long-term sustainability as a Coinbase proxy.

Outlook remains cautious due to structural concerns about the option income strategy capping upside potential. Investment opportunity centers on high distribution yields, but risks include underlying asset volatility and negative media sentiment questioning the fund's value proposition for long-term holders.

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

Returns comparison

Trailing returns across standard periods

About YieldMax COIN Option Income Strategy ETF

CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.

Read more on CONY

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA